The maintenance of effect with tildrakizumab over 5 years is independent of baseline characteristics: pooled analysis of the phase 3 studies reSURFACE 1 and reSURFACE 2 in patients with moderate to severe psoriasis

被引：0
|
作者：
Thaci, Diamant [1 ]
Piaserico, Stefano [2 ]
Diemert, Sebastian [3 ]
Torres, Tiago [4 ]
机构：
[1] Univ Lubeck, Inst & Exzellenzzentrum Entzundungsmed, Lubeck, Germany
[2] Univ Padua, Dept Med, Unit Dermatol, Padua, Italy
[3] Almirall Hermal GmbH, Reinbek, Germany
[4] Ctr Hosp Univ Porto, Dept Dermatol, Porto, Portugal
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P071
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [41] Incidence of cardiovascular events in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: pooled analysis from a phase 2 and two phase 3 trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Peserico, A.
    Fumero, E.
    Mendelsohn, A.
    Rozzo, S.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 46 - 47
  • [42] Ixekizumab in patients with psoriasis and psoriatic arthritis: Pooled analysis of three phase 3 studies in moderate-to-severe psoriasis
    Gottlieb, Alice
    Papp, Kim
    Duffin, Kristina Callis
    Birbara, Charles
    Cuchacovich, Raquel
    Shuler, Catherine
    Burge, Russel
    Erickson, Janelle
    Kerr, Lisa
    Mease, Philip
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S26 - S26
  • [43] The application of Dermatology Life Quality Index-Relevant (DLQI-R) in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: post hoc analysis from the reSURFACE 2 phase III trial
    Laws, P.
    Gaarn Du Jardin, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E41 - E42
  • [44] Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
    Warren, R. B.
    Carrascosa, J. M.
    Fumero, E.
    Schoenenberger, A.
    Lebwohl, M. G.
    Szepietowski, J. C.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (04) : 919 - 927
  • [45] Application of the statistical method to convert published PASI 50/75/90/100 into absolute PASI response rate in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab based on data from two pivotal phase 3 studies (reSURFACE 1/2)
    Dykukha, Igor
    Schoenenberger, Andreu
    Kasujee, Ismail
    Mrowietz, Ulrich
    Vonthein, Reinhard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB79 - AB79
  • [46] Long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or non-responders to etanercept: results from the reSURFACE 2 phase 3 trial through 148 weeks
    Iversen, L.
    Reich, K.
    Griffiths, C.
    Peserico, A.
    Kimball, A.
    Pau-Charles, I.
    Blauvelt, A.
    Thaci, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 56 - 56
  • [47] Efficacy of tildrakizumab for moderate-to-severe chronic plaque psoriasis: Pooled analysis of 3 randomised controlled studies at weeks 12 and 28
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Kimball, A.
    Tyring, S.
    Sinclair, R.
    Thaci, D.
    Li, Q.
    Cichanowitzs, N.
    Greens, S.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 108 - 109
  • [48] Impact of baseline characteristics on the efficacy of ixekizumab in patients with moderate to severe psoriasis in a phase 2 study
    Papp, Kim
    Zhu, Baojin
    Leonardi, Craig
    Cameron, Gregory
    Erickson, Janelle
    Heffernan, Michael
    Banerjee, Subhashis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB171 - AB171
  • [49] Secukinumab is independent of the initial Severity of illness in Patients with moderate to severe Plaque-Type Psoriasis vigorously: pooled Analysis of four Phase 3 Studies
    Gerdes, S.
    Spelman, L.
    Blauvelt, A.
    Loffler, J.
    Fox, T.
    Papavassilis, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 122 - 122
  • [50] The impact of apremilast therapy on work productivity among patients with moderate to severe plaque psoriasis: Pooled analysis of 2 phase 3 studies
    Papp, Kim
    Zhang, Frank
    Tencer, Tom
    Li, Stan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB255 - AB255
12345